187 related articles for article (PubMed ID: 24201803)
21. Alterations in the proteome of the NHERF1 knockout mouse jejunal brush border membrane vesicles.
Donowitz M; Singh S; Singh P; Salahuddin FF; Chen Y; Chakraborty M; Murtazina R; Gucek M; Cole RN; Zachos NC; Kovbasnjuk O; Broere N; Smalley-Freed WG; Reynolds AB; Hubbard AL; Seidler U; Weinman E; de Jonge HR; Hogema BM; Li X
Physiol Genomics; 2010 Nov; 42A(3):200-10. PubMed ID: 20736413
[TBL] [Abstract][Full Text] [Related]
22. Distribution dynamics and functional importance of NHERF1 in regulation of Mrp-2 trafficking in hepatocytes.
Karvar S; Suda J; Zhu L; Rockey DC
Am J Physiol Cell Physiol; 2014 Oct; 307(8):C727-37. PubMed ID: 25163515
[TBL] [Abstract][Full Text] [Related]
23. Specificity of NHERF1 regulation of GPCR signaling and function in human airway smooth muscle.
Pera T; Tompkins E; Katz M; Wang B; Deshpande DA; Weinman EJ; Penn RB
FASEB J; 2019 Aug; 33(8):9008-9016. PubMed ID: 31042404
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of the Na⁺/ H⁺ exchanger regulatory factor 1 (NHERF1) protein in cancer.
Saponaro C; Malfettone A; Dell'Endice TS; Brunetti AE; Achimas-Cadariu P; Paradiso A; Mangia A
Cancer Biomark; 2014; 14(2-3):177-84. PubMed ID: 24878819
[TBL] [Abstract][Full Text] [Related]
25. NHERF1/EBP50 is a new marker in colorectal cancer.
Hayashi Y; Molina JR; Hamilton SR; Georgescu MM
Neoplasia; 2010 Dec; 12(12):1013-22. PubMed ID: 21170265
[TBL] [Abstract][Full Text] [Related]
26. Involvement of nuclear NHERF1 in colorectal cancer progression.
Mangia A; Saponaro C; Malfettone A; Bisceglie D; Bellizzi A; Asselti M; Popescu O; Reshkin SJ; Paradiso A; Simone G
Oncol Rep; 2012 Sep; 28(3):889-94. PubMed ID: 22766563
[TBL] [Abstract][Full Text] [Related]
27. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
[TBL] [Abstract][Full Text] [Related]
28. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
29. Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas.
Liu J; Wei XL; Huang WH; Chen CF; Bai JW; Zhang GJ
PLoS One; 2012; 7(12):e52675. PubMed ID: 23300741
[TBL] [Abstract][Full Text] [Related]
30. Dynamic relocalization of NHERF1 mediates chemotactic migration of ovarian cancer cells toward lysophosphatidic acid stimulation.
Oh YS; Heo K; Kim EK; Jang JH; Bae SS; Park JB; Kim YH; Song M; Kim SR; Ryu SH; Kim IH; Suh PG
Exp Mol Med; 2017 Jul; 49(7):e351. PubMed ID: 28684865
[TBL] [Abstract][Full Text] [Related]
31. Na+-H+ exchanger regulatory factor 1 is a PDZ scaffold for the astroglial glutamate transporter GLAST.
Lee A; Rayfield A; Hryciw DH; Ma TA; Wang D; Pow D; Broer S; Yun C; Poronnik P
Glia; 2007 Jan; 55(2):119-29. PubMed ID: 17048262
[TBL] [Abstract][Full Text] [Related]
32. Repressing of NHERF1 inhibits liver cancer progression by promoting the production of ROS.
Sun J; Li P; Yang J
Biochem Biophys Res Commun; 2019 Jan; 509(1):8-15. PubMed ID: 30581004
[TBL] [Abstract][Full Text] [Related]
33. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
34. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
Shaaban AM; Green AR; Karthik S; Alizadeh Y; Hughes TA; Harkins L; Ellis IO; Robertson JF; Paish EC; Saunders PT; Groome NP; Speirs V
Clin Cancer Res; 2008 Aug; 14(16):5228-35. PubMed ID: 18698041
[TBL] [Abstract][Full Text] [Related]
35. NHERF1/EBP50 controls lactation by establishing basal membrane polarity complexes with prolactin receptor.
Morales FC; Hayashi Y; van Pelt CS; Georgescu MM
Cell Death Dis; 2012 Sep; 3(9):e391. PubMed ID: 22992649
[TBL] [Abstract][Full Text] [Related]
36. β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients.
Schirosi L; Mazzotta A; Opinto G; Pinto R; Graziano G; Tommasi S; Fucci L; Simone G; Mangia A
Oncotarget; 2016 Oct; 7(42):67841-67850. PubMed ID: 27765918
[TBL] [Abstract][Full Text] [Related]
37. NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway.
Gu Y; Yu H; Hao C; Martin TA; Hargest R; He J; Cheng S; Jiang WG
Oncotarget; 2017 Jan; 8(5):7753-7765. PubMed ID: 27999191
[TBL] [Abstract][Full Text] [Related]
38. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
39. Similar expression pattern of NHERF1 and EZRIN in papillary but not in solid areas of human serous ovarian carcinomas.
Demacopulo B; Lema BE; Cabrini RL; Kreimann EL
Acta Histochem; 2016 Oct; 118(8):797-805. PubMed ID: 27823775
[TBL] [Abstract][Full Text] [Related]
40. Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.
Mirza S; Rakha EA; Alshareeda A; Mohibi S; Zhao X; Katafiasz BJ; Wang J; Gurumurthy CB; Bele A; Ellis IO; Green AR; Band H; Band V
Breast Cancer Res Treat; 2013 Feb; 137(3):721-31. PubMed ID: 23288344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
